BeiGene LTD News Releases http://ir.beigene.com/ BeiGene LTD News Releases en 百济神州收回在研抗PD-1抗体替雷利珠单抗全球授权 http://ir.beigene.com/news-releases/news-release-details/baijishenzhoushouhuizaiyankangpd Mon, 17 Jun 2019 07:00:00 -0400 BeiGene LTD News Releases 10886 BeiGene Regains Full Global Rights to Its Investigational Anti-PD-1 Antibody Tislelizumab http://ir.beigene.com/news-releases/news-release-details/beigene-regains-full-global-rights-its-investigational-anti-pd-1 CAMBRIDGE, Mass. and BEIJING, China , June 17, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today Mon, 17 Jun 2019 07:00:00 -0400 BeiGene LTD News Releases 10881 百济神州在第24届欧洲血液学协会(EHA)年会上以海报的形式公布三项泽布替尼临床数据 http://ir.beigene.com/news-releases/news-release-details-135 Fri, 14 Jun 2019 02:30:00 -0400 BeiGene LTD News Releases 10871 BeiGene Announces Updated Results from a Pivotal Phase 2 Study of Tislelizumab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma at the 24th Congress of the European Hematology Association (EHA) http://ir.beigene.com/news-releases/news-release-details/beigene-announces-updated-results-pivotal-phase-2-study Company to Host Investor Conference Call and Webcast of Mid-2019 Clinical Data Updates on Thursday, June 20 at 8:00 a.m. EDT CAMBRIDGE, Mass. and BEIJING, China , June 14, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on Fri, 14 Jun 2019 02:30:00 -0400 BeiGene LTD News Releases 10861 百济神州在第24届欧洲血液学协会(EHA)年会上公布一项替雷利珠单抗用于治疗复发或难治性经典型霍奇金淋巴瘤中国患者的关键性2期临床研究更新结果 http://ir.beigene.com/news-releases/news-release-details-136 Fri, 14 Jun 2019 02:30:00 -0400 BeiGene LTD News Releases 10876 BeiGene Announces Clinical Results from Three Posters on Zanubrutinib Presented at the 24th Congress of European Hematology Association (EHA) http://ir.beigene.com/news-releases/news-release-details/beigene-announces-clinical-results-three-posters-zanubrutinib First Preliminary Data from Exploratory MYD88 WT Patient Cohort in Phase 3 Trial in Waldenström’s Macroglobulinemia (WM) ; Updated Phase 1/2 WM Data; and Pooled Safety Data Analysis on Zanubrutinib in B-Cell Malignancies Presented Company to Host Investor Conference Call and Webcast of Mid-2019 Fri, 14 Jun 2019 02:30:00 -0400 BeiGene LTD News Releases 10866 百济神州将在第15届国际恶性淋巴瘤会议(ICML)上公布多项泽布替尼临床数据 http://ir.beigene.com/news-releases/news-release-details-134 Wed, 12 Jun 2019 04:00:00 -0400 BeiGene LTD News Releases 10856 BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 15th International Conference on Malignant Lymphoma (ICML) http://ir.beigene.com/news-releases/news-release-details/beigene-announces-clinical-data-zanubrutinib-be-presented-15th Company to Host Investor Conference Call and Webcast of Mid-2019 Clinical Data Updates on Thursday, June 20 at 8:00 a.m. EDT CAMBRIDGE, Mass. and BEIJING, China , June 12, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on Wed, 12 Jun 2019 04:00:00 -0400 BeiGene LTD News Releases 10846 百济神州宣布将于高盛第40届年度全球健康大会上发表演讲 http://ir.beigene.com/news-releases/news-release-details-133 Wed, 05 Jun 2019 07:00:00 -0400 BeiGene LTD News Releases 10781 BeiGene to Present at the Goldman Sachs 40th Annual Global Healthcare Conference http://ir.beigene.com/news-releases/news-release-details/beigene-present-goldman-sachs-40th-annual-global-healthcare CAMBRIDGE, Mass. and BEIJING, China , June 05, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today Wed, 05 Jun 2019 07:00:00 -0400 BeiGene LTD News Releases 10776